Group One Trading
BCLI

Group One Trading’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

Group One Trading’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-10,200
Closed -$23.2K – 7588
2024
Q4 		$23.2K Buy
10,200
+8,680
+571% +$16K ﹤0.01% 5591
2024
Q3 		$5.25K Sell
1,520
-680
-31% -$3.21K ﹤0.01% 5863
2024
Q2 		$11.2K Sell
2,200
-1,380
-39% -$10.3K ﹤0.01% 5590
2024
Q1 		$30.3K Buy
3,580
+3,340
+1,392% +$18.4K ﹤0.01% 5112
2023
Q4 		$983 Sell
240
-5,840
-96% -$17.5K ﹤0.01% 6988
2023
Q3 		$18.2K Sell
6,080
-20,593
-77% -$468K ﹤0.01% 5948
2023
Q2 		$824K Buy
26,673
+22,926
+612% +$950K ﹤0.01% 2535
2023
Q1 		$185K Sell
3,747
-8,646
-70% -$251K ﹤0.01% 3745
2022
Q4 		$305K Sell
12,393
-1,040
-8% -$38.9K ﹤0.01% 3485
2022
Q3 		$891K Sell
13,433
-787
-6% -$39.5K ﹤0.01% 2688
2022
Q2 		$589K Buy
14,220
+6,047
+74% +$272K ﹤0.01% 3270
2022
Q1 		$412K Sell
8,173
-3,954
-33% -$194K ﹤0.01% 4025
2021
Q4 		$728K Sell
12,127
-966
-7% -$47.5K ﹤0.01% 3682
2021
Q3 		$648K Sell
13,093
-440
-3% -$23.1K ﹤0.01% 3902
2021
Q2 		$771K Sell
13,533
-1,974
-13% -$105K ﹤0.01% 3700
2021
Q1 		$891K Buy
15,507
+5,294
+52% +$400K ﹤0.01% 3370
2020
Q4 		$693K Buy
10,213
+2,706
+36% +$369K ﹤0.01% 2979
2020
Q3 		$1.91M Sell
7,507
-3,220
-30% -$659K 0.01% 1635
2020
Q2 		$1.8M Sell
10,727
-2,733
-20% -$295K 0.01% 1539
2020
Q1 		$937K Buy
13,460
+12,480
+1,273% +$974K 0.01% 1572
2019
Q4 		$63K Sell
980
-373
-28% -$21.6K ﹤0.01% 3896
2019
Q3 		$79K Buy
1,353
+1,273
+1,591% +$75.1K ﹤0.01% 3713
2019
Q2 		$5K Buy
+80
New +$4.66K ﹤0.01% 4592
2018
Q3 		– Sell
-1,247
Closed -$73K – 5179
2018
Q2 		$73K Buy
1,247
+960
+334% +$56.5K ﹤0.01% 3733
2018
Q1 		$14K Sell
287
-1,066
-79% -$53.7K ﹤0.01% 4202
2017
Q4 		$80K Buy
1,353
+73
+6% +$4.37K ﹤0.01% 3483
2017
Q3 		$79K Buy
1,280
+1,247
+3,779% +$80.7K ﹤0.01% 3374
2017
Q2 		$2K Sell
33
-1,127
-97% -$69.5K ﹤0.01% 4556
2017
Q1 		$74K Buy
1,160
+700
+152% +$36.4K ﹤0.01% 3165
2016
Q4 		$18K Buy
460
+360
+360% +$12.5K ﹤0.01% 3733
2016
Q3 		$4K Buy
+100
New +$3.74K ﹤0.01% 4249

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Group One Trading's BCLI Position: Q4 2024 in Review

Group One Trading sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q4 2024, closing a stake of 3,117 shares — an estimated $5.76K sold.

Group One Trading first reported a position in BCLI in Q2 2015 and held it in 21 quarters. The position peaked at $537K in Q1 2023. 34 funds tracked by Wall St. Rank hold BCLI as of Q4 2024.

  • Group One Trading reported no remaining BRAINSTORM CELL THERAPUTC position as of Q4 2024 after selling out during the quarter.
  • Group One Trading sold 3,117 BRAINSTORM CELL THERAPUTC shares in Q4 2024, an estimated $5.76K.
  • Group One Trading first reported a position in BRAINSTORM CELL THERAPUTC in Q2 2015 and held it in 21 quarters.
  • Group One Trading's BRAINSTORM CELL THERAPUTC position peaked at $537K in Q1 2023.
  • 34 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q4 2024.

Based on Group One Trading's 13F filing for Q4 2024, filed 14 Feb 2025.